Lexeo Therapeutics (LXEO) Share-based Compensation (2022 - 2026)
Lexeo Therapeutics (LXEO) posted Share-based Compensation of $2.8 million for Q1 2026, up 1.55% sequentially from $2.7 million in Q4 2025, and down 25.48% YoY from $3.7 million in Q1 2025.
Lexeo Therapeutics (LXEO) Share-based Compensation (2022 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Share-based Compensation for 5 years, with the latest figure at $2.8 million in Q1 2026.
- Quarterly Share-based Compensation fell 25.48% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.2 million (down 19.15% YoY) and the FY2025 annual result came in at $12.1 million, down 2.74% from the prior year.
- Share-based Compensation rose to $2.8 million in Q1 2026 per LXEO's latest filing, from $2.7 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $3.8 million in Q3 2024 and troughed at $397000.0 in Q1 2023.
- A 5-year average of $2.1 million and a median of $2.7 million in 2025 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation jumped 487.15% in 2024, then slumped 30.05% in 2025.
- Over 5 years, Share-based Compensation stood at $521000.0 in 2022, then surged by 54.32% to $804000.0 in 2023, then soared by 336.19% to $3.5 million in 2024, then slipped by 22.64% to $2.7 million in 2025, then rose by 1.55% to $2.8 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2.8 million, $2.7 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - | 5.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.69 Mn |
| Jun 30, 2026 | 5.69 Mn |
| Mar 31, 2026 | 2.76 Mn |
| Mar 31, 2026 | 2.76 Mn |
| Dec 31, 2025 | 2.71 Mn |
| Dec 31, 2025 | 2.71 Mn |
| Sep 30, 2025 | 2.65 Mn |
| Sep 30, 2025 | 2.65 Mn |
| Jun 30, 2025 | 3.07 Mn |
| Jun 30, 2025 | 3.07 Mn |
| Mar 31, 2025 | 3.70 Mn |
| Mar 31, 2025 | 3.70 Mn |
| Dec 31, 2024 | 3.51 Mn |
| Dec 31, 2024 | 3.51 Mn |
| Sep 30, 2024 | 3.79 Mn |
| Sep 30, 2024 | 3.79 Mn |
| Jun 30, 2024 | 2.85 Mn |
| Jun 30, 2024 | 2.85 Mn |
| Mar 31, 2024 | 2.33 Mn |
| Mar 31, 2024 | 2.33 Mn |